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MLP and CARP are linked to chronic PKCa
signalling in dilated cardiomyopathy
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MLP (muscle LIM protein)-deficient mice count among the first mouse models for dilated
cardiomyopathy (DCM), yet the exact role of MLP in cardiac signalling processes is still
enigmatic. Elevated PKCa signalling activity is known to be an important contributor to heart
failure. Here we show that MLP directly inhibits the activity of PKCa. In end-stage DCM, PKCa
is concentrated at the intercalated disc of cardiomyocytes, where it is sequestered by the
adaptor protein CARP in a multiprotein complex together with PLCb1. In mice deficient for
both MLP and CARP the chronic PKCa signalling chain at the intercalated disc is broken and
they remain healthy. Our results suggest that the main role of MLP in heart lies in the direct
inhibition of PKCa and that chronic uninhibited PKCa activity at the intercalated disc in the
absence of functional MLP leads to heart failure.
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M
LP (Muscle LIM protein, encoded by the Csrp3 gene)
was initially discovered as a protein up-regulated in
skeletal muscle following denervation1. It was
subsequently shown to be expressed only in the heart and in
adult slow-twitch skeletal muscle, and suggested to play a role
during muscle differentiation1,2. MLP consists of two LIM
domains, structural domains composed of two zinc fingers,
which are well known for their role in protein–protein
interactions3,4. Among the many binding partners that were
described for MLP are the cytoskeletal proteins actin, a-actinin,
N-RAP, telethonin (T-cap) and spectrin as well as the skeletal
muscle transcription factors MyoD, MRF4 and myogenin5–9.
Based on these interactions and the presence of a nuclear
localization signal it was proposed that MLP acts as a signalling
protein between the myofilaments or the cytoplasm, and the
nucleus in myocytes, which is responsive to pharmacological or
mechanical stimuli10. Pathological mutations in MLP can lead to
familial hypertrophic cardiomyopathy (HCM)11 or dilated
cardiomyopathy (DCM)8.
Mice deficient for MLP (MLP knockouts) count among the
first published models for DCM in a genetically manipulated
animal12. They show all the anatomical and physiological
hallmarks of DCM, and present with up-regulated expression
levels of classical biomarkers for hypertrophy such as ANF (atrial
natriuretic factor), BNP (brain natriuretic peptide) and b-myosin
heavy chain as well as stress markers such as CARP (Cardiac-
specific ankyrin repeat protein, CARP1/Ankrd1)12. While MLP
knockout mice have been used by many laboratories as a mouse
model to investigate DCM, the exact role that MLP plays in
myocytes remains unclear. It was proposed that MLP could act as
a mechanosensor at the Z-disc transmitting stress signals to the
nucleus8,10,13. While signalling roles of MLP in the heart are well
characterized, its function as a mechanosensor is less clear.
Considering its molecular structure and subcellular localization, it
is not obvious how a 20 kDa protein that exclusively consists of
LIM domains can sense changes in mechanical force. Given that
LIM domains have well-known protein–protein interaction
interfaces3,4, it seems more likely that MLP functions in signal
transmission rather than as a direct mechanosensor. Additionally,
the exclusive Z-disc localization has been challenged, since several
groups have reported a more widespread distribution throughout
several subcellular compartments in myocytes both for
endogenous and transfected MLP, including the nucleus,
plasma membrane, cytoplasm, cytoskeleton and myofibrillar
localizations other than the Z-disc6,10,11,13,14.
Over the years numerous rescue models were published using
MLP knockout mice including double knockout mice with the
SERCA-2A (Sarcoplasmic reticulum Caþ þ ATPase) regulator
phospholamban15 and overexpression of calcineurin16. Other
MLP knockout rescue reports involve inhibition of adrenergic
signalling17,18 and interference with PKCa (Protein Kinase C)
signalling19,20.
Increased PKCa expression and activity are well established in
end stage heart failure models in rodents (for recent reviews
see21,22). The phosphorylation substrates for PKCa range from
phospholamban to sarcomeric proteins such as troponin and
titin, and phosphatases such as PP2A with ensuing effects on
calcium handling and contractility19,23–25.
Intrigued by recent propositions that MLP may interact
directly with PKCa26, and reports that MLP expression is
down-regulated in failing mouse and human hearts7,27,
we speculated that MLP may directly affect PKCa activity.
Our assays reveal that the presence of MLP inhibits autopho-
sphorylation of PKCa as well as phosphorylation of downstream
targets such as phospholamban. We demonstrate that in failing
hearts PKCa is concentrated at the intercalated discs (ID)
(specialized cell–cell contacts in cardiomyocytes) in a complex
with the adaptor protein CARP1 and PLCb1. In double knockout
mice for CARP1 and MLP (CMP1), PKCa is no longer detected
at the ID and the DCM phenotype does not develop. This
is accompanied by normalized PKCa phosphorylation and
expression levels. We propose a signalosome complex consisting
of muscle ankyrin repeat proteins (MARPs) and PKCa that is
regulated by MLP and whose persistent activation may play a role
in chronic stress signalling in the failing heart.
Results
MLP directly inhibits PKCa activity. To investigate the
possibility that MLP can directly modulate the activity of PKCa,
we carried out in vitro phosphorylation assays using
recombinantly expressed protein. Autoradiography showed that
increasing amounts of MLP lead to decreased PKCa
autophosphorylation and a decreased phosphorylation of the
PKCa substrate phospholamban (Fig. 1a, for quantification see
Fig. 1b). Furthermore, we found that MLP itself is a potential
substrate of PKCa (Fig. 1a) and that gene mutations associated
with human HCM result in reduced phosphorylation of MLP,
while DCM-causing mutations show increased phosphorylation
(Fig. 1c,d). Intriguingly, MLP phosphorylation appears to be
significantly increased in heart samples of DCM patients (IDCM)
as compared to non-failing (NF) controls (Fig. 1e,f). A similar
shift in MLP phosphorylation was observed in Ga (q)
overexpressing mice (Supplementary Fig. 1a,b), a mouse model
for cardiac contractile failure28. A potential role of wild-type
(WT) MLP in modulating PKCa signalling and activity in
long-term heart failure may explain why the lack of MLP leads to
DCM, and why all strategies that interfered with PKCa signalling
prevented the development of a DCM phenotype in the
MLP-deficient background19,20.
PKCa concentrates at the ID in failing hearts. While an increase
in PKCa expression and activity is well established in the failing
rodent heart21, the situation in humans is less clear25,29,30.
Analysis of PKCa/b expression in heart samples from patients
with idiopathic dilated cardiomyopathy (IDCM) by immuno-
blotting revealed a marked up-regulation of PKC phosphorylation
at Thr638/641 in most patient samples (Fig. 2a). Confocal
microscopy on immunostained heart sections from DCM patients
showed a remarkable concentration of PKCa at the ID (Fig. 2b,
quantification in 2c), which was not as evident in heart samples
from NF controls. This supports published data that reported an
increased signal for PKCa at the ID in human heart failure29.
How does PKCa specifically target the ID? CARP1 is a stress
marker that is consistently up-regulated in heart failure12,31 and a
well-known scaffold protein (for reviews see refs 32,33).
Immunoblot data (Fig. 2a) showed increased expression of
CARP1, but not the closely related CARP2/Ankrd2 in failing
human heart samples. At the cellular level CARP1 is known to
localize to the sarcomere and the nucleus, with increased nuclear
presence following mechanical strain34. We observed no
differences in nuclear versus cytoplasmic localization of CARP1
in either normal or DCM hearts (Supplementary Fig. 1c).
However, in all functionally compromised hearts that we
studied (MLP knockout and human DCM samples), CARP1
translocated from the sarcomere to the ID (Fig. 2d,
for quantification see Supplementary Fig. 1d,e), whereas the
localization of CARP2 was less affected (Fig. 2d, for quantification
see Supplementary Fig. 1e). ID association for both proteins was
recently also described by Jasnic-Savovic and colleagues35.
Consistent with a previously reported interaction between
CARP1 and phospholipase-C (PLC)36, we demonstrated in
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pull-down assays that the coiled coil region of PLCb1, the main
PLC isoform in hearts37, binds to both CARP1 and CARP2
(Fig. 2e). Protein complementation assays revealed that all CARP
family members can interact with the coiled coil region of PLCb1
and that this interaction happens in an antiparallel fashion
(Fig. 2f). To investigate whether this complex also occurs in
cardiac tissue in situ, we carried out immunoprecipitation
experiments on cardiac extracts from MLP knockout hearts.
CARP1 is exclusively expressed in cardiomyocytes and cannot be
detected in fibroblasts (Supplementary Fig. 1f), therefore
confirming that we specifically assayed the cardiomyocyte
signalosome. Using CARP1 antibodies, we identified the
presence of a signalosome complex in MLP knockout hearts
containing CARP1, CARP2, PKCa and PLCb1 (Fig. 2g). In
contrast, these proteins were not pulled down from WT or
CARP1 knockout hearts, adding support to our hypothesis that
this complex only assembles in DCM/failing hearts. Using
recombinant CARP1 or CARP2, we demonstrated that it is also
possible to pull-down PLCb1 and PKCa from MLP knockout
hearts (Supplementary Fig. 1g). In left ventricle extracts from a
subset of end-stage DCM patients the entire complex could be
pulled down (Supplementary Fig. 1h).
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Figure 1 | MLP is a substrate and inhibitor of PKCa kinase activity in vitro. (a) In vitro kinase assay using PKCa and GST tagged phospholamban
cytoplasmic N-terminus (GST-PLN(N)) as substrate with increasing GST-MLP or GST amounts. Shown are representative autoradiography images for
phosphorylated proteins (upper panel) or Coomassie staining for total proteins (lower panel). Dashed line indicates that proteins were run on the same gel,
but imaged using different exposure times. (b) Quantification of GST-PLN(N) phosphorylation or PKCa auto-phosphorylation with increasing GST-MLP or
GST concentrations. Mean values with s.e., sample size (n) and P values are shown. (c) In vitro kinase assay using PKCa and GST tagged WT and mutant
MLP as substrate. Representative autoradiography images for either Leu44Pro (L44P), Lys69Arg (K69R), Gly72Arg (G72R) mutant MLP (top panel), or
Ser54Arg/Glu55Gly (S54R/E55G) or Cys58Gly (C58G; bottom panel) mutant MLP (bottom panel) in comparison with WT MLP are shown. Dashed line
indicates proteins were run on the same gel, but non-consecutive. (d) Quantification of MLP phosphorylation by PKCa. Phosphorylation efficiency of WT
MLP was arbitrarily set to 1. Mutants identified in human HCM patients show lower MLP phosphorylation, while MLP mutants associated with DCM
display increased phosphorylation values. A representative Coomassie stained gel showing total GST-tagged MLP used for in vitro kinase assays is depicted
(bottom panel; dashed line indicates that proteins were run on the same gel, but non consecutive.). Shown are mean values and s.e., as well as P values and
sample sizes (n, in brackets below bar graphs). (e,f) Analysis of MLP phosphorylation in IDCM. (e) Quantification of MLP phosphorylation indicates
significantly elevated phosphorylation levels in IDCM patients, compared to NF controls. Shown are mean values and s.e., as well as sample size (n, in
brackets below bar graphs), and P values. (f) MLP phosphorylation levels for quantification in (e) were determined by Phostag analysis. SDS samples of
protein extracts of NF and IDCM patient heart samples were run on conventional SDS PAGE (middle) and on 12% polyacrylamide gels with 50 mM Phostag
reagent (top) and immunoblotted for MLP. A human control sample with uncharacterized disease status (ctl) showing non-phosphorylated (P0) and
phosphorylated (P1) MLP was used to indicate Phostag gel migration pattern. Phosphorylated proteins (P1) migrate slower due to their interaction with the
Phostag reagent compared to unphosphorylated protein (P0). GAPDH (bottom) was used to show equal loading.
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These results indicate that CARP1 and CARP2 can sequester
PKCa into a complex with PLCb1. In the failing heart CARP1 is
up-regulated and relocates from the sarcomere to the ID. This
relocation and the ensuing retention of PKCa at the ID appear to
be the crucial step in maladaptive signalling in failing hearts.
PKC activity affects CARP and MLP expression. CARP1 is
reportedly a target for many protein kinases including PKCa38,
which we recently demonstrated through in vitro kinase assays39.
Since CARP1 up-regulation and subcellular relocation appear to
be crucial in setting up the pathological signalosome complex
together with PKCa and PLC1b at the ID, we considered the
possibility of an initial crosstalk between PKCa and CARP.
Addition of kinase inhibitors to cultures of neonatal mouse
cardiomyocytes (NMC) revealed that exposure to PKC inhibitors
(bisindolylmaleimide (BI) or calphostin C (Ca)) not only reduced
PKCa phosphorylation levels at Thr638/641, but also
downregulated CARP1 expression levels (Fig. 3a). No effect was
seen with a Map kinase kinase inhibitor (U0126; U0), again
supporting the idea that the effect on CARP1 expression levels
may be due to PKCa activity (Fig. 3a). The reduction in CARP1
expression following PKC inhibition could also be observed in
cardiomyocytes cultured over several days as well as in vivo, when
MLP knockout mice were peritoneally injected with BI (Fig. 3b,c,
Supplementary Fig. 1i). The effect was not limited to CARP1, but
also extended to CARP2 expression (Fig. 3b,c), which was
significantly down-regulated in hearts of BI treated mice. More
intriguingly, however, was the effect we observed on MLP
phosphorylation and expression levels. PKC inhibition by BI
decreased MLP expression levels, and more importantly MLP
phosphorylation in cardiomyocytes (Fig. 3d). These data indicate
that MLP is a direct phosphorylation target of PKC, and that this
phosphorylation may affect MLP activity and protein levels
(Supplementary Fig. 1k). In immunofluorescence-stained heart
sections, PKC inhibition shifted CARP1 but not CARP2
localization from a more pronounced ID association to an
increased sarcomeric signal (Fig. 3e, for quantification see 3f).
Label-free measurements of NMC contractility demonstrated that
inhibition of PKCa by BI normalized the higher beating
frequencies usually observed in neonatal MLP knockout
cardiomyocytes compared to WT controls (Fig. 3g,h).
These results show that elevated PKCa phosphorylation
increases CARP expression levels. This is accompanied by the
subcellular relocalization of both PKCa and CARP1 to the ID.
The assembly of a signalosome consisting of CARP, PKCa and
PLCb1 at the ID leads to a stabilization of PKCa signalling
activity. Inhibition of PKCa results in down-regulation of CARP
expression, changes its subcellular targeting and probably leads to
the disassembly of the signalosome. In addition, PKCa inhibition
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Figure 2 | PKCa is sequestered in a multiprotein complex with CARP at
the ID of failing hearts. (a) Analysis of PKCa phosphorylation levels
(Thr638/641), PKCa, CARP1 and CARP2 protein levels in whole extracts of
NF, familial DCM (FDCM) and IDCM patient heart samples. Cardiac actin
was used as a loading control. Dotted lines indicate that samples were run
on the same gel, but non-consecutive. (b) Immunofluorescence staining of
human NF and IDCM heart sections using antibodies against PKCa (right,
green). Plakoglobin and a-actinin were used as counterstains (red and blue
in overlay, respectively). Scale bar¼ 10mm. (c) Quantification of
immunofluorescence intensity (F F0) over IDs from (b) shows that PKCa
levels at the ID are increased in IDCM samples compared to NF controls.
Sample sizes for analysed ID were n¼ 24 from three NF heart samples and
n¼46 from five IDCM hearts. (d) Immunofluorescence staining of human
NF and IDCM heart sections using antibodies against CARP1 (top, green in
overlay) and CARP2 (bottom; green in overlay). The sarcomeric association
(arrows) of CARP1 and CARP2 decreases in IDCM in favour of increased ID
localization (arrowheads; for quantification see Supplementary Fig. 1d,e).
Plakoglobin and a-actinin were used as counterstains (red and blue in
overlay, respectively). Scale bar¼ 10 mm. (e) Pull-down assay of GFP-PLCb1
(phospholipase-C) with GST-CARP1, GST-CARP2 or GST indicated the
coiled-coil domain within PLCb1 as minimal binding site. Ponceau stain was
used to visualize GST-CARP1 and GST-CARP2 protein levels, while equal
amounts of GST (not shown) were used as a control. (f) Protein
complementation assay using YFP (split-fluorescent protein assay)
demonstrating antiparallel association (green in overlay) between coiled-
coil domains of PLCb1 tagged on the N-terminus with a YFP N-terminal
fragment (YN) and CARP1 tagged on the C-terminus with YFP C-terminal
fragment (YC; upper right panel). No association was seen when CARP1
was tagged on the N-terminus with YFP C-terminal fragment (upper left
panel). Split-fluorescent protein assay also demonstrated antiparallel
association (green in overlay) between coiled-coil domains of PLCb1 tagged
on the N-terminus with a YFP N-terminal fragment (YN) and either CARP2
(lower left panel) or CARP3 (lower right panel) tagged on the C-terminus
with YFP C-terminal fragment (YC). Transfection efficiency was validated
with a GFP antibody (red in the overlay), and DAPI (blue in overlay) was
used as counterstain. Scale bar¼ 20mm. (g) Co-immunoprecipitation of
PLCb1, PKCa, CARP2 and CARP1 from soluble heart extracts of adult WT,
MLP knockout or CARP1 knockout mice by using either CARP1 antibodies or
normal rabbit IgG as control (visible in Ponceau stain).
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in WT cardiomyocytes leads to a decrease in MLP phosphoryla-
tion and expression.
We propose that acute signalling of this complex may be
beneficial for the adaptation of the heart to stress40, while its
chronic or pathological activation is maladaptive.
Absent DCM phenotype in MLP CARP1/CARP2 double
knockout mice. If CARP1 is indeed a crucial adaptor required to
recruit PKCa stably to the ID, and to trigger pathological sig-
nalling in failing hearts, then its removal should prevent the
development of heart failure in MLP knockout mice. Genetic
ablation of any of the MARP family members in mice (CARP1/
Ankrd1/MARP—encoded by the Ankrd1 gene; CARP2/Ankrd2/
ARPP encoded by the Ankrd2 gene; CARP3/Ankrd23/DARP—
encoded by the Ankrd23 gene) had no effect on heart function at
baseline, even in the case of a triple knockout41. To test our
hypothesis, we crossed MLP knockout mice with the three MARP
knockout lines and examined their cardiac phenotype.
Immunoblot analysis of MLP and MARP expression revealed
basal expression of CARP1, but no CARP2 in control hearts
(Fig. 4a and Supplementary Fig. 2a,b). Hearts of MLP knockouts
displayed increased expression as well as altered posttranslational
modification of CARP1 and induced CARP2 expression (Fig. 4a,
Supplementary Fig. 2a–c). CARP3 was not expressed in control
hearts, and was not induced in MLP knockout hearts
(Supplementary Fig. 2a). Histological and functional analyses
revealed the previously reported phenotype of MLP knockout
hearts (that is, dilation and heart failure12); in contrast double
knockout mice for MLP and CARP1 (CMP1), and MLP and
CARP2 (CMP2) had normal healthy hearts. Thus, the DCM
phenotype does not develop in the absence of CARP1 or CARP2
(Fig. 4b,c, Supplementary Fig. 2d,e, Supplementary Tables 1 and
2). The hearts of double knockout mice for MLP and CARP3
(CMP3) were dilated and exhibited heart failure similar to the
single MLP knockout mice (Fig. 4b,c, Supplementary Fig. 2d,e,
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Figure 3 | Inhibition of PKCa affects CARP1 expression and localization and decreases MLP phosphorylation. (a) Effect of PKC inhibitors (10 mM BI
I-HCl; BI or 5 mM calphostin C; Ca) or MAP kinase kinase inhibitor (1mM U0126; U0) treatment for 24 h on PKCa phosphorylation, PKCa and CARP1
expression levels in NMC compared to untreated controls ( ). Dotted line indicates that samples were run on the same gel, but non-consecutive. GAPDH
was used as loading control. (b) Immunoblot analysis of total cardiac samples from untreated ( ), vehicle treated (DMSO, V) or BI treated adult MLP
knockout mice (24 h after vehicle or BI-injection), blotted for phospho-PKCa (Thr638/641), PKCa, CARP1 or CARP2. GAPDH was used as a loading
control. Shown are representative blots and quantification of changes for PKCa phosphorylation as well as CARP1 and CARP2 protein levels (c). Sample
sizes for untreated controls and BI-treated animals were 4 and 3, respectively. P values are indicated in the figure. (d) BI treatment of NRC for 24 h leads to
decreased MLP phosphorylation and protein level (see also Supplementary Fig. 1j,k). SDS samples of protein extracts from vehicle treated (V) or BI-treated
NRC were run on conventional SDS PAGE (middle) and on 12% polyacrylamide gels containing 50mM Phostag reagent (top) and immunoblotted for MLP.
Phosphorylated MLP proteins (P1) migrate slower due to their interaction with the Phostag reagent, compared to unphosphorylated protein (P0). Phostag
profile plot analysis of band intensities (right panel) revealed presence of three distinct P1 MLP phosphorylation bands (P1-a, P1-b and P1-c), which are
putatively caused by several distinct phosphorylation sites in MLP. One of these phosphorylation sites (P1-c) is changed significantly upon BI treatment (red
curve) compared to vehicle control (blue curve). Shown are normalized average band intensities and s.e. GAPDH was used as loading control (bottom).
(e) Representative immunofluorescence images of adult heart sections from BI and vehicle treated MLP knockout mice stained with antibodies against
CARP1 (green), a-actinin (blue) and plakoglobin (red). Scale bar¼ 10mm. (f) Analysis of fluorescence intensity ratios (I ID/S) of CARP1 (left panel) and
CARP2 stainings (right panel) between the ID region and the sarcomere (S) of either BI-treated or vehicle-treated 4-month-old MLP mice (see
Supplementary Fig. 1d for methodology). Sample sizes (n in base of the bar; from two hearts per sample) and P values are indicated in the figure; $ denotes
low expression of CARP1/CARP2 in BI treated hearts (as shown in Fig. 3b). (g,h) Label free impedance analysis of spontaneously contracting WTand MLP
knockout NMC using the RTCA cardio system. Representative images of real-time beating activity of WT and MLP mouse cardiomyocytes (g) and
quantification of their beating frequency (h). Effect of BI treatment on MLP cardiomyocyte beating frequencies (h, right panel). Bar graphs depict mean
values and s.e. The number of independently measured wells (n in base of bar) and P values are indicated.
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Supplementary Table 3). CMP3 hearts had elevated expression
levels of CARP1 and CARP2 as well as increased PKCa
phosphorylation, suggesting activity of the same maladaptive
signalling complex that we propose for MLP knockout mice
(Supplementary Fig. 2a,f). The absence of a failing heart
phenotype in the CMP1 animals was accompanied by
redistribution of CARP2 to the sarcomeres (Fig. 4d, for
quantification see Supplementary Fig. 2g). Most importantly
PKCa no longer concentrated at the ID, while the PLCb1
localization was indistinguishable between genotypes (Fig. 4e,
Supplementary Fig. 2h,i). Analysis of PKCa phosphorylation
levels revealed their normalization to control levels in the
CMP1 heart compared to the MLP knockout heart (Fig. 4f).
This suggests that it is the concentration of PKCa at the ID that
triggers its pathological activity. Previously we characterized
pathological changes at the cellular level in murine and human
DCM samples such as elevated expression levels of N-RAP at
the ID and re-expression of the foetal M-band marker
EH-myomesin7,42,43. These changes were no longer seen in
CMP1 or CMP2, but were still evident in CMP3 hearts
(Supplementary Fig. 3a,b). However, while the lack of CARP1
or CARP2 expression prevents the development of a DCM
phenotype, biomarkers for hypertrophy such as ANF, BNP and
skeletal actin continued to be elevated at the mRNA level in
CMP1 and CMP2 mice (Supplementary Fig. 4a–c). Also,
double knockout hearts still showed some evidence of fibrosis
(Supplementary Fig. 4d–f), although the amount was markedly
reduced compared to MLP knockout mice.
In conclusion, we propose that the existence of a multiprotein
complex consisting of CARP, PKCa and PLCb1 at the ID of
failing hearts is crucial for the maintenance of pathological
signalling activity of PKCa. MLP can directly inhibit PKCa
activity, and its absence is sufficient to lead to a DCM phenotype
over time. Removal of CARP leads to the dissolution of the
complex, where PKCa no longer concentrates at the ID,
preventing the DCM phenotype in MLP knockout mice.
Discussion
We demonstrate here the existence of a multiprotein complex
composed of PKCa, PLC1b, CARP1 and CARP2 at the ID
specifically in failing hearts. The retention of PKCa to this
signalosome at the ID may lead to an amplification of signalling.
The persistent shift in subcellular localization makes the
difference between acute activation of PKCa that is beneficial
for the heart to cope with transient stress, and chronic activation,
which leads to detrimental downstream effects on calcium
handling and contractile parameters. We propose that the up-
regulation in expression and relocation of CARP1 or CARP2
from a sarcomeric localization to the ID is the crucial switch
between acute and chronic PKCa activation (Fig. 5). We further
show that MLP can directly inhibit PKCa activity in vitro, and
demonstrate that removal of CARP by genetic means prevents
the formation of this maladaptive signalling complex,
thereby preventing the morphological, functional and molecular
phenotype of DCM in MLP knockout mice.
These results explain at a molecular level, why previous
strategies that prevented the development of a DCM phenotype
in the MLP knockout mouse were successful15,19,20. Under
normal circumstances MLP reduces excessive PKCa signalling in
the heart. In MLP knockout mice this does no longer happen and
DCM develops. Direct interference with the maladaptive PKCa
signalling pathway by genetic or pharmacological strategies thus
rescues the effect of the lack of MLP. The novel role of MLP as a
PKCa inhibitor could also provide an explanation why
overexpression of MLP does not have drastic effects on heart
function under basal conditions44. Removal of phospholamban,
which was found to rescue the MLP knockout phenotype15, leads
to a reduction of free cytosolic calcium known to be required for
PKCa activation.
We also noted that MLP itself is a substrate for PKCa activity.
Indeed, DCM patient samples that show higher PKCa phosphor-
ylation levels correlated with increased MLP phosphorylation
levels compared to NF controls. Moreover we observed that
DCM-causing MLP mutants were hyper-phosphorylated by
PKCa in vitro, while MLP mutants that were associated with
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Figure 4 | DCM in MLP knockout mice is prevented in the absence of
CARP1 or CARP2. (a) Expression levels of CARP1, MLP and GAPDH as
control in total heart extracts of WT, MLP knockout, CARP1 knockout and
CARP1-MLP double knockout (CMP1) mice. (b) Cardiac morphology of WT,
MLP, CARP1, CARP2 or CARP3 knockouts, as well as CARP1-MLP (CMP1),
CARP2-MLP (CMP2) and CARP3-MLP (CMP3) double knockouts.
Hematoxylin-eosin stained frozen heart sections are shown. Scale
bar¼ 2mm. (c) Analysis of cardiac function using M-mode transthoracic
echocardiography and representative M-mode images of hearts from WT,
MLP, CARP1, CMP1, CARP2, CMP2, CARP3 and CMP3 animals.
(d) Immunofluorescence staining of frozen heart sections from adult WT,
MLP knockout and CMP1 double knockout animals stained with antibodies
against CARP1 (green in overlay, top two panels) and CARP2 (green in
overlay, bottom two panels). Arrowheads indicate ID and arrows show
Z-disc localization, respectively. (e) Frozen sections of adult WT, CARP1,
MLP knockout and CMP1 hearts stained with antibodies against PLCb1 and
PKCa (all green; see Supplementary Fig. 2h,i for quantification of PKCa
localization at ID). (d,e) Plakoglobin and a-actinin were used as
counterstains (red and blue in overlay, respectively). Scale bars¼ 10mm.
(f) Immunoblot for PLCb1, phospho-PKCa/bII (T638/641), and PKCa in
WT, CARP1 knockout, MLP knockout and CMP1 double knockout total heart
extracts. GAPDH was used as a loading control.
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the development of HCM were hypo-phosphorylated. Inhibition
of PKCa activity in vitro leads to decreased MLP phosphorylation
and expression in cardiomyocytes. The exciting finding that the
MLP phosphorylation state can be modulated by PKCa,
correlates with different forms of cardiomyopathy and may affect
its protein levels and/or activity again underlines the important
role of this protein in cardiac stress signalling. At present it is
unknown whether mutations in MLP or its various posttransla-
tional modifications have an effect on oligomerization, which
determines the subcellular localization and actin bundling activity
of MLP13,14. Phostag blots of neonatal rat cardiomyocytes (NRC)
indicate the presence of several distinct MLP phosphorylation
sites, one of which was significantly changed upon PKC
inhibition. It will be intriguing to investigate which
posttranslational modifications of MLP indeed change its cell-
biological properties. We propose that these posttranslational
modifications of MLP are key to its biological function, and may
ultimately determine where, when and how effectively it interferes
with PKCa signalling.
CARP1 has for a long time been associated with
mechanosignalling34 and was shown to be up-regulated in heart
failure by several studies12,31,45. Recently its upregulated
expression was shown to correlate directly with heart failure
progression in IDCM46. So far most studies have proposed that
nuclear signalling of CARP via ERK1/2 to molecules such as p53
and GATA4 is crucial for a hypertrophic response47. While there
are conflicting results on the effect of CARP1 on ERK1/2
activation40,47, it appears to be increasingly recognized that stress
sensing complexes associated with the titin I-band region,
containing CARP1, or FHL1/2 and RAF/MEK/ERK may be
partially responsible for mediating a hypertrophic response in
hearts48. Our results now show that in heart failure CARP1 seems
to be involved in a different signalling cascade at a distinct
subcellular localization, namely boosting maladaptive PKCa
signalling at the ID. Mutations in CARP1 were shown to cause
both HCM and DCM49,50 and to display both gain of function
and dominant negative effects on the contractile behaviour of
engineered heart tissues51. We propose that whether mutant
CARP1 leads to HCM or DCM may be correlated to differential
effects on protein–protein interaction and in particular distinct
activation of the two signalling pathways via ERK1/2 from the
sarcomere to the nucleus (HCM) or via PKCa at the ID (DCM).
Our results demonstrate that one of the main differences
between a healthy and a failing heart is the presence of PKCa at
the ID. The analysis of PKCa/b expression levels in human hearts
was inconclusive and it seems to be the change in subcellular
targeting rather than mere expression levels that makes the
crucial difference between a healthy and a failing heart. Why
would active PKCa/b at the ID be so detrimental for the heart?
Cell membranes are known to be the major site of PKC function
(for review see ref. 52) and the signalosome complex that we
describe here appears to be similar to previously described
scaffold interactions that were shown to be crucial for PKC
regulation52. Increased translocation of PKCa from the cytosolic
to the membranous fraction marked the transition from pressure
overload induced hypertrophy to congestive heart failure in guinea
pigs53. In addition, constitutively active PKCa at the ID may
interfere with another level of regulation in the challenged heart.
b-adrenergic receptors are known to become insensitive following
PKCa activation54 and adrenergic signalling is well known to play
a role in heart disease55. Adrenergic receptors were previously
shown to be concentrated at the ID in cardiomyocytes56. A failure
to respond to fine-tuning by adrenergic signalling as shown by the
altered contractile behaviour that we observed in cultured
cardiomyocytes from MLP knockout mice, may over time lead
to a failing heart phenotype.
Taken together, our results highlight novel roles for MLP and
CARP in pathological signalling via their interactions with PKCa.
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This signalosome seems to be crucial for eliciting the maximal
maladaptive response in the stressed heart, and CARP may be the
proposed missing link57. Modulation of this complex may offer
new therapeutic options to prevent heart failure.
Methods
Bacterial protein expression and in vitro kinase assay. Expression of
GST-fusion proteins was done using BL21 cells (C601003; Invitrogen; Life
Technologies, Carlsbad, CA). BL21 cells were transformed with GST-expression
vectors (GST-C1, GST-CARP1, GST-CARP2, GST-MLP (WT and mutants),
GST-PLN(N)) and grown in 400ml LB-medium supplemented with 50 mgml 1
carbenicillin on an orbital shaker at 37 C to an OD600 of41. After incubation on
ice for 15min, expression of GST or GST-fusion proteins was induced by addition
of 0.2mM IPTG (Isopropyl b-D-1-thiogalactopyranoside) and production of
proteins was allowed to proceed over night at 18 C. Cells were collected by
centrifugation and lysed into 40ml ice cold lysis buffer (150mM NaCl, 10mM
Tris-HCl pH 8, 1% Triton X100), followed by sonication for 1min at 4 C at 70%
output (Vibracell, Sonics & Materials Inc., Newtown, CT). Removal of insoluble
cell debris was done by centrifugation (45min at 11,000 r.p.m., 4 C; Sorvall) and
the supernatant was incubated with 400ml glutathione-sepharose beads (Pharma-
cia) for 2 h at 4 C with agitation. After washing of beads with ice cold PBS for four
times, bound protein was eluted with GST-elution buffer (150mM NaCl, 50mM
Tris-HCl pH 7.4, 150mM reduced glutathione) and dialyzed over night at 4 C
against dialysis buffer (20mM HEPES pH7.4, 10mM MgSO4, 0.1mM CaCl2).
Measurement of protein concentration was done using the Bradford assay (BioRad)
or through densitometry of Coomassie stained SDS-PAGE gels. Proteins were
frozen in liquid nitrogen and stored at  80 C until further use in in vitro kinase
assays or for GST pull-down assays.
For in vitro kinase assays 2 mg of GST-PLN(N) or GST-MLP (WT or mutant)
were combined with purified PKCa (approximately 10 ng/reaction, P0329,
Sigma-Aldrich) in kinase buffer (20mM HEPES KOH pH7.4, 10mM MgSO4,
0.1mM CaCl2) supplemented with either radioactively labelled [gamma-32P]ATP
(Amersham Biosciences) or unlabelled ATP (20mM) and increasing amounts
(0.25 mg, 0.5 mg or 1 mg) of either GST-MLP or GST. The reaction mix was supplied
with a combination of 1 mgml 1 phosphatidylserine (1,2-diacyl-sn-glycero-3-
phospho-L-serine) and 2 mgml 1 diacylglycerol (DAG; 1,2-Dioleoyl-sn-glycerol)
dissolved in resuspension buffer (10mM HEPES pH 7.4, 0.3% Triton X-100).
Following incubation at 30 C for 30min, samples were mixed with SDS-sample
buffer (BioRad) and separated using SDS-PAGE. For radioactively labelled
proteins, gels were coomassie-stained or fixed, dried on a BioRad gel dryer and
analysed using X-ray films and autoradiography39. Densitometric quantification of
phosphorylation levels was done by scanning X-ray films followed by measurement
of band intensity using ImageJ (NIH).
Human tissues. Human specimens were obtained from the Sydney Heart Bank at
the University of Sydney and signed patient consent was obtained for all samples in
this tissue bank. All failing samples were collected in the heart transplant theatres at
St Vincent’s Hospital from patients in end-stage heart failure and were frozen in
liquid nitrogen within 15–20min of the loss of coronary artery flow (cross-clamp).
Human Research Ethics Committee approval was obtained by St Vincent’s
Hospital (#H03/118), and by the University of Sydney Human Research Ethics
Committee (#12146, #159401). Human tissue was used in accordance with the
ethical guidelines of King’s College London (College Research Ethical Committee
04/05–74; REC reference 12/EM/0106), under current UK law. For protein,
histological and immunofluorescence analysis, samples from the left ventricular
free walls of patients in end-stage heart failure with familial (FDCM) or IDCM
were used. NF donor hearts, which were cardiopleged, but not required for heart
transplantation, were provided by the Australian Red Cross Blood Transfusion
Service. Typically these hearts were not transplanted because of tissue
incompatibility.
Generation of constructs. Bacterial and eukaryotic expression constructs for
human MLP (HSU49837), the cytoplasmic domain of mouse phospholamban
(PLN(N), amino acids 1–34; NM_023129), human CARP1/Ankrd1 (NM_014391),
human CARP2/Ankrd2 (NM_020349), human CARP3/Ankrd23 (NM_144994),
human phospholipase C b1 coiled-coil domains (NM_015192, amino acids
978–1138) were done by amplifying the coding sequence via PCR from a human
cardiac cDNA library (Clontech) or from mouse cardiac cDNA and subsequent
in-frame cloning into the pEGFP-C1 (Clontech), pEGFP-N1 (Clontech), HA-N1
(a modified version of the pEGFP-N1 vector that replaces the EGFP coding
sequence with the HA-tag), or pGST-C1 vector (a modified version of the
pGEX-2T bacterial expression vector; Amersham Pharmacia39). Generation of
bacterial GST-tagged mutant human MLP expression constructs was done as
described previously11.
Generation of protein complementation constructs was done through in-frame
ligation of the coiled-coil region of CARP1 (amino acids 1–122), the coiled-coil
region of CARP2 (amino acids 1–146), the coiled-coil region of CARP3 (amino
acids 1–109), and the coiled-coil region of human phospholipase C b1 (PLCb1;
amino acids 980–1140) into the protein complementation vectors (split-YFP)
YN-C1, YC-C1 or YC-N1 (ref. 39). This effectively generates either N-terminally
tagged fusion proteins with the N-terminal (YN) or C-terminal (YC) half of YFP,
or C-terminally tagged fusion proteins with the C-terminal half of YFP.
All constructs were verified for in-frame integration and correct sequence by
sequencing.
Protein expression analysis. Total protein extracts of hearts for immunoblot or
biochemical analysis were generated by homogenizing ventricular samples either
directly into SDS-sample buffer (BioRad) or ice-cold IP-buffer (150mM NaCl,
Tris-HCl pH 8, 1mM DTT, 1 Complete Protease Inhibitor EDTA-free (Roche),
1 PhosSTOP (Roche), 0.2% NP-40, 0.2% SDS) by using a polytron blade
homogenizer (Pro Scientific Inc). Total proteins from NMC, neonatal cardiac
fibroblasts or transfected COS-1 cell cultures were extracted by washing cells with
PBS at room temperature and solubilization of cells directly into SDS-sample buffer
or ice-cold IP-buffer using a cell scraper. Protein extracts were immediately
transferred into Eppendorf tubes and stored on ice for immediate use or
snap-frozen into liquid nitrogen and stored at  20 C or  80 C. Protein
amounts were normalized by densitometry of Coomassie stained SDS PAGE.
Normalized total protein extracts were run on uniform 15% acrylamide, 10%
acrylamide, or 4–20% acrylamide gradient SDS-PAGE gels (BioRad, Invitrogen),
followed by immunoblotting on nitrocellulose membranes (BioRad) using wet blot
technology. The nitrocellulose membranes were stained with Ponceau Red, blocked
with 5% non fat dry milk (Sainsbury’s) or 3% Bovine Serum Albumin (Sigma) in
Low Salt Buffer (0.9% NaCl, 9mM Tris pH 7.4, 0.1% Tween-20) and sequential
incubation with the appropriate primary and secondary antibodies with
intermittent washing in Low Salt Buffer was performed. Results from the
chemiluminescence reaction were visualized on Fuji medical X-ray films.
For 2D gel analysis, protein samples were diluted 1:1 into IEF sample buffer
(Life Technologies), and first dimension was run on IEF pH3–10 gels (Life
Technologies), followed by 12% acrylamide SDS-PAGE according to the
manufacturer’s instructions.
Phostag gels. For analysis of MLP phosphorylation levels, 20mg of frozen cardiac
tissue samples were homogenized into 200 ml freshly prepared ice-cold TLB lysis
buffer (20mM Tris HCL pH 7.6, 138mM NaCl, 5% glycerol, 1% Triton, 5mM
DTT, 0.5mM Sodium ortho-vanadate, Mini Protease inhibitor tablet (no EDTA;
Roche), Phos-stop tablet (Roche)). Samples were briefly sonicated, incubated on
ice for 20min, centrifuged at 4 C at 14,000 r.p.m. for 15min, and supernatants
were used for further analysis via Phostag gel analysis58 after determination of
protein concentrations. Protein samples with normalized concentrations were
supplemented with SDS sample buffer, boiled for 5min, and either run on a 12%
poly-acrylamide SDS-PAGE, or a 12% poly-acrylamide SDS PAGE supplemented
with 50mM Manganese Phostag (WAKO Chemicals). After end of electrophoresis,
gels were washed once in immunoblot transfer buffer supplemented with 10mM
EDTA for 10min, followed by a wash in immunoblot transfer buffer for another
10min, and prepared for immunoblot transfer and subsequent detection and
analysis following standard procedures.
Co-immunoprecipitation and GST pull-down assays. For biochemical
protein–protein interaction assays, protein extracts in IP-buffer were sonicated
for 1min at 30% output on ice (Vibracell, Sonics & Materials Inc.), followed by
centrifugation at 14,000 r.p.m. (4 C) for 10min to separate insoluble proteins.
Soluble proteins were either incubated with 1 mg of primary antibody or control
serum for 2 h, or incubated with 2 mg of GST or GST-fusion protein at 4 C.
Following immuno-complex formation in co-immunoprecipitation assays, protein
extracts were incubated with protein G-linked magnetic beads (Dynabeads;
Invitrogen) for an additional hour at 4 C with agitation. For GST pull-down
assays, protein extracts were incubated with glutathione-sepharose 4B resin
(Pharmacia) for an additional 2 h at 4 C with agitation. After incubation, beads
were washed three times with ice-cold PBS, resuspended in sample buffer (BioRad),
and analysed by SDS PAGE, followed by immunoblotting on nitrocellulose
membranes39.
Animals. All procedures were reviewed and approved by the Animal Care and Use
Committee at the University of California San Diego. MLP and MARP knockout
mice as well as Ga (q) overexpressing mice were previously described12,28,41.
All animals were in a mixed sv129/black swiss background. For physiological
experiments only male mice were used, samples used for immunohistology and
immunoblotting were from both genders. Unless stated otherwise, animals in the
age range between 4 and 8 months were used for the experiments. Oligonucleotides
used for genotyping via PCR analysis of tail DNA can be found in Supplementary
Table 4.
The mice were fed ad libitum with a standard diet and maintained in a
temperature and light-controlled room (22 C, 14 h light/10 h dark). Treatment of
MLP knockout animals with PKC inhibitor was done similar to a previously
described method20. In short, 4-months old male MLP mice were injected
subcutaneous with a single dose of either PKC inhibitor BI I-HCl (BI; sc-24004,
Santa Cruz Biotechnology, 1 mg g 1 body weight) or DMSO (vehicle). Ventricular
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heart tissue of mice was dissected after 24 h following the injection and snap frozen
in liquid nitrogen for further analysis, or processed for immunofluorescence
analysis.
The protocol for animal handling and treatment procedures was in accordance
with the guidelines of the Laboratory Animal Services at the University of
California, San Diego and guidelines presented in the National Research Council’s
(NCR) ‘Guide for Care and Use of Laboratory Animals’ published by the Institute
for Laboratory Animal Research of the National Academy of Science, Bethesda,
MD, 2011.
For echocardiography analysis 2-, 4-, 6- and 12-month-old male control, MLP,
MARP and MLP-MARP double knockout mice were analysed. For protein, mRNA,
histological, immunofluorescence and morphological analysis, the left ventricular
free wall of hearts from 3–9-month-old adult male and female mice were used.
Investigation of gross cardiac morphology by histology used whole hearts that
included ventricles and atria.
Transthoracic echocardiography. Adult male mice at 2, 4, 6 and 12 months of age
were analysed as previously described41. Briefly, mice were anesthetized with 1%
isoflurane and cardiac function was measured with a Philips Sonos 5500 machine
(Philips Medical Systems, Andover, MA) equipped with a 15-MHz transducer.
M-mode tracings of semi-conscious mice were recorded and analysed for left
ventricular posterior wall and inter-ventricular septal thickness, as well as left
ventricular chamber dimensions (LVID) at both end systole and end diastole.
Heart contractility, shown as fractional shortening (%FS) was calculated as
previously described41.
Antibodies. The following primary antibodies were used for biochemical
analysis of protein and phosphorylation levels (dilutions given in brackets are
for immunoblotting, the antibodies were used 10 times more concentrated for
immunohistology): GAPDH (clone 6C5; Santa Cruz Biotechnology; 1:1000),
cardiac Actin (clone Ac1–20.4.2, Progen Biotechnik; 1:2000), collagen-1 (ab34710,
Abcam; 1:1000), smooth-muscle actin (clone 1A4, DAKO: 1:1000), CD-31/
PECAM-1 (550274, BD Pharmingen; 1:5000), a-sarcomeric actinin (clone EA53,
A7811, Sigma-Aldrich; 1:5000), PLCb1 (sc-205, Santa Cruz Biotechnology; 1:1000),
PKCa (sc-208, Santa Cruz Biotechnology; #2056, Cell Signalling; 1:1000),
phospho-PKCa (T638/641 #9375, Cell Signalling; 1:1000), plakoglobin/g-catenin
(SAB2500802, Sigma-Aldrich; 1:1000), sarcomeric myosin-heavy chain (A4.1025,
Developmental Studies Hybridoma Bank, University of Iowa; 1:100), PDGF-
Receptor a (AF1062, R&D; 1:1000), GFP-tag (11814460001 Roche; 1:1000).
Normal rabbit IgG was from Santa Cruz Biotechnology (sc-2027), while normal
donkey serum was from Jackson ImmunoResearch.
Polyclonal antibodies against MARP proteins (used 1:1000) were either
produced in house or a kind gift of Dr Siegfried Labeit (University of Heidelberg)
and produced by Myomedix. Monoclonal antibodies against myomesin (used
1:200) and MLP (used 1:1000) were described previously7,11. Polyclonal antibodies
against EH-myomesin (used 1:500 for immunofluorescence) were generated by
Dr Irina Agarkova42. Polyclonal antibodies against N-RAP (used 1:100 for
immunofluorescence) were generated by BioScience (Go¨ttingen, Germany).
All fluorescently or enzymatically linked secondary antibodies were either from
DAKO, Jackson ImmunoResearch or GE Healthcare Life Sciences and used at
1:100 (fluorescent) or 1:1000 (enzymatic) dilutions.
Quantitative real-time PCR analysis (qPCR). Ventricular samples were
homogenized directly into Trizol reagent (Invitrogen) to extract total RNA
according to the manufacturers instructions. First strand cDNA was generated
from 2 mg of total mRNA using random hexamers and Superscript II reverse
transcriptase. Oligonucleotides optimized for qPCR (Supplementary Table 5) of
murine ANF, BNP, skeletal actin, CARP1 and GAPDH were used in reactions
employing the PerfeCTa SYBR green real-time PCR mix (Quanta BioSciences) and
a CFX96 thermocycler (BioRad). Samples were normalized to GAPDH. If not
stated otherwise, three biological replicates were analysed per sample group.
Cell culture. The isolation of NMC and NRC was performed using collagenase/
dispase digestion, respectively59. Hearts from neonatal rats and mice were initially
dissected in PBS containing 20mM BDM (2,3-butanedione monoxime; Sigma) and
minced. Subsequently they were subjected to digestion with collagenase/dispase
(Roche; 15mg in 10ml L15 medium with 20mM BDM) for 3 20min at 37 C
with gentle agitation. Alternatively, cardiomyocytes were isolated using the
Neonatal Cardiomyocyte isolation kit (Miltenyi Biotec) according to the
manufacturer’s instructions. Individual cells were released by trituration with a
10ml tissue culture pipette and undigested tissue pieces were removed using a cell
strainer (Falcon). After centrifugation at 80 g, the pellet of isolated cells was
resuspended in Plating Medium (68% DMEM, 17% Medium M199, 10% horse
serum, 5% foetal calf serum, 4mM glutamine, and 1% penicillin-streptomycin, all
from Sigma), plated into collagen-coated plastic dishes and incubated over night.
The next day, the cells were switched to Maintenance Medium (20% Medium
M199, 75% DBSS-K, 4% horse serum, 4mM glutamine, 1% penicillin/
streptomycin, 0.1mM phenylephrine; DBSS-K: 6.8 g l 1 NaCl, 0.14mM
NaH2PO4, 0.2mM CaCl2, 0.2mM MgSO4, 1mM dextrose, 2.7mM NaHCO3).
Treatment of NMC and NRC using BI I-HCl (BI; sc-24004, Santa Cruz
Biotechnology, 10mM), calphostin C (Ca; sc-3545, Santa Cruz Biotechnology,
5 mM) or U0126 (U0; sc-222395, Santa Cruz Biotechnology, 1 mM) was done by
supplementing the maintenance medium for 24 h with inhibitors or vehicle,
followed by biochemical analysis of protein extracts.
For analysis of CARP1 and MLP expression in cardiomyocyte versus cardiac
fibroblasts, cardiac fibroblasts were separated during the NMC isolation procedure,
and cultured for an additional 2 days in DMEM (high glucose), supplemented with
10% foetal calf serum and 1% penicillin/streptomycin medium.
COS-1 cells were cultured in DMEM with 10% foetal calf serum and transfected
mixing 1 mg of plasmid DNA and 3 ml of Lipofectamine-2000 (Life Technologies
Carlsbad, CA) in 300 ml DMEM and adding the mix to the cells.
Immunofluorescence and histology. Immunostaining of frozen sections on
glass-slides (Colorfrost Plus, Thermo Scientific) and cells in cell-culture dishes
(Nunc) was done as described previously7,39. In brief, immunostaining of frozen
heart sections was achieved by fixing 12 mm sections (Leica CM1850 cryostat) in
ice-cold acetone for 5min at  20 C, followed by rehydration of the tissue section
with PBS at room temperature for 5min. Cultured NMC or COS-1 cells were fixed
with 4% paraformaldehyde solution in PBS for 5min at 37 C, followed by a wash
with PBS at room temperature. After permeabilization using 0.2% triton-X100 in
PBS for 5min, sections or cells were incubated with primary antibodies in gold
buffer (GB; 20mM Tris-HCl, pH 7.5, 155mM NaCl, 2mM ethylene glycol
tetraacetic acid, 2mM MgCl2, 1% bovine serum albumin; for antibody dilutions see
Antibodies paragraph) supplemented with 5% normal donkey serum over night at
4 C in a humid chamber. After washing of sections or cells for three times with
PBS to remove unbound primary antibodies, sections or cells were incubated with
secondary antibodies in GB supplemented with 5% normal donkey serum and
2mgml 1 40 ,6-diamidino-2-phenylindole (10 mgml 1 DAPI, Sigma-Aldrich; for
antibody dilutions see Antibodies paragraph) at room temperature in a humid
chamber. Following washing of sections or cells with PBS (three times) for 5min at
room temperature, sections or cells were embedded in fluorescent mounting
medium (DAKO) and mounted with coverslips.
For hematoxylin-eosin staining, 20 mm frozen sections were fixed for 5min at
room temperature using a 4% paraformaldehyde solution in PBS. Following
fixation, sections were washed in water, incubated in Weigert’s Hematoxylin
solution (HT1079, Sigma-Aldrich) for 5min, briefly rinsed with water and
counterstained with Eosin-Y solution (Richard Allan Sci.) for 2min. After
dehydration of sections using increasing percentages of alcohol (50% for 2min,
75% for 2min, 95% for 2min, twice 100% for 5min), samples were washed twice in
Histo-Clear (National Diagnostics) for 10min and mounted using Permount
(Fisher Sci.).
Confocal microscopy. Fluorescently stained samples were imaged using an
Olympus Fluoview 1000 confocal microscope equipped with 40 oil immersion
lens, or a LEICA TCS-SP5 confocal microscope equipped with a 63 glycerol
immersion objective in sequential scanning mode and zoom rates between one and
three. Histology samples were recorded by a SPOT camera and imaging software,
using a Nikon epifluorescence microscope equipped with a 5x air objective in
bright-field mode.
Image processing and statistical analysis. Images were processed using ImageJ
(NIH) equipped with the LOCI bio-formats plugin and Photoshop (Adobe).
Statistical analysis was done using Excel (Microsoft). Data presented are mean
values±s.e. Significance was evaluated by the two-tailed student’s t-test. Sample
size (n-values) and P values are indicated in the figures and/or figure legends.
For analysis of PKC localization over ID (Fig. 2c, Supplementary Fig. 2h),
profile plots were measured over aligned ID using the ImageJ plugin ‘RGB profile
plot’. Plot values (PKC fluorescence intensity and plakoglobin fluorescence
intensity) were exported into Excel. The plakoglobin profile was used to establish
the precise localization of the ID. The corresponding PKC intensity (F) at the ID
was subtracted with the background PKC intensity (F0) to generate the background
corrected profile PKCa plots (F F0). Profile plots were centred at the ID, and the
average profile plot and s.e. were calculated for each group, and used to generate
the figure. Data presented in Fig. 2c and Supplementary Fig. 2h are mean
values±s.e. Significance was evaluated by the two-tailed student’s t-test over
fluorescence intensity values (F F0) at the ID. Sample size (n-values) and P values
are indicated in the figures and/or figure legends.
For Phostag profile plot analysis (Fig. 3d), MLP bands were analysed using
ImageJ and the ‘Plot Profile’ tool. Data were exported to Excel, aligned and
normalized, and the resulting average plot profile for each group, including s.e.
were used to generate the figure. Significance was evaluated by student’s t-test
analysis.
For analysis of CARP1, CARP2 and a-Actinin fluorescence intensity ratios
(IID/S) between the ID and the sarcomere (S), identical-sized boxes encircling a
portion of the ID, and an adjacent sarcomere were selected, and RGB values were
measured in ImageJ using the ‘RGB measure’ plugin. After measurement of
fluorescence intensities, individual and average intensity ratios as well as s.e. and
significance was calculated in Excel. Data presented in Fig. 3f, Supplementary
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Figs 1e and 2g are mean values±s.e. Significance was evaluated by the two-tailed
student’s t-test. Sample size (n-values) and P values are indicated in the figures
and/or figure legends.
Label-free measurement of cardiomyocyte contraction. Live label-free
impedance measurements (cell index) of cardiomyocyte beating frequency (beats
per minute) and contraction behaviour were done using the xCelligence RTCA
cardio system (ACEA Biosciences)60. Basal contractile behaviour of cells was
analysed two days after plating of NMCs into 96 well plates. The effect of
increasing concentrations (0.5, 1, 5 and 10 mM) of the PKC inhibitor BI I-HCl (BI)
in comparison to untreated cells was evaluated 21–22 h after addition of the small
molecule inhibitor to the maintenance culture medium.
Data availability. All relevant data are available from the authors.
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